Abstract 4528
Background
Triple negative breast cancer carries a poor prognosis. Cytotoxic chemotherapy (chemo) is the standard of care. Recent data demonstrate that immunotherapy and anti-body drug conjugate based therapy can improve outcomes. Nevertheless survival remains poor. This SLR and MA was performed to assess the efficacy of current treatments for 2 nd line (2L) mTNBC.
Methods
EMBASE, MEDLINE, Cochrane databases were systematically searched from database inception to December 2018 for relevant studies of mTNBC with any systemic therapies in metastatic disease. Relevant congresses proceedings since 2016 and ClinicalTrials.gov were also searched. This SLR followed PRISMA guidelines with scope defined in terms of PICOS criteria (Population, Intervention, Comparators, Outcomes and Study design). Weighted averages (WA) for outcomes by treatment arm and line of therapy (LOT) were calculated. In addition, MA of overall response rate (ORR) among patients receiving single agent chemo (single chemo) as 2L and first line or later (1L+) was carried out using random-effects modeling for ORR.
Results
44 original studies were selected: 22 with 1L+, 7 with 2L, 15 with 2L or later (2L+). WAs of outcomes are presented in the Table. WAs of ORR for single chemo were less than ORR for combination chemo or chemo & biologics. No treatment showed consistently better survival over other treatments across all 3 groupings. MA of ORR in patients receiving single chemo as 2L and 1L+ were 11.9% (95% CI: 4.6, 20.8) and 15.6% (95% CI: 8.8-32.9), respectively. Table. Weighted Averages of Clinical Outcomes by Treatment and Line of Therapy.Table:
360P
Treatment | Line of Therapy | Overall Response Rate (%) | Progression Free Survival (median months) | Overall Survival (median months) |
---|---|---|---|---|
Single agent chemotherapy | 1L+ | 14.6 | 2.3 | 10.8 |
2L | 14.3 | 2.4 | 12.6 | |
2L+ | - | 3.1 | 12.3 | |
Combination chemotherapy | 1L+ | 29.7 | 4.4 | 10.5 |
2L | 31.0 | 4.1 | 10.0 | |
2L+ | - | 2.9 | 8.1 | |
Chemotherapy & Biologics | 1L+ | 22.6 | 2.9 | 10.6 |
2L | 35.8 | 5.6 | 17.9 | |
2L+ | 21.2 | 3.5 | 10.7 |
Conclusions
There is no clear standard of care in 2L TNBC. Response rates are low for single chemo and although response rates improve with combination therapies, no treatment regimen has demonstrated definitive improvement in outcomes. These results reinforce the need for new treatment strategies for mTNBC after 1L.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Purple Squirrel Economics.
Funding
Seattle Genetics, Inc.
Disclosure
P.A. Kaufman: Full / Part-time employment: Seattle Genetics, Inc. J. Feliciano: Full / Part-time employment: Seattle Genetics, Inc. P. Garfin: Full / Part-time employment: Seattle Genetics, Inc. L. Brown: Full / Part-time employment: Seattle Genetics, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract